M&A
confidence high
sentiment positive
materiality 0.85
Jazz to acquire Actio Biosciences for $820M upfront, up to $500M milestones
Jazz Pharmaceuticals plc
- Jazz to acquire Actio Biosciences for $820M upfront plus up to $500M in approval/sales milestones.
- Lead asset ABS-1230: first-in-class KCNT1 inhibitor for KCNT1+ epilepsy, no FDA-approved therapies.
- ABS-1230 has FDA Fast Track, Rare Pediatric Disease, Orphan Drug designations; accepted into RDEP program.
- Transaction expected to close Q4 2026; funded via cash on hand and existing facilities.
- Actio spins out new entity with TRPV4 inhibitor ABS-0871; Jazz takes minority stake.